
OncLive News Network®
Series
All
All


Emerging Therapies in Relapsed or Refractory Multiple Myeloma
Kenneth Shain, MD, PhD reviews advances in treatment of relapsed and refractory multiple myeloma and data presented at 2021 International Myeloma Workshop.

Updates in CLL: Optimizing Testing Rates
Preferences for conducting molecular testing in patients with chronic lymphocytic leukemia to guide treatment decisions based on evolving novel combination regimens used as frontline therapy.

Approval of Tisotumab Vedotin in The Treatment of Cervical Cancer
Expert gynecologic oncologist Rebecca Arend, MD, MPH, addresses data from the 2021 ESMO meeting and the approval of tisotumab vedotin for patients with cervical cancer.

Antibody-Drug Conjugates in NSCLC: Update on TROPION-PanTumor01 Data
Rebecca Suk Heist, MD, MPH, and Solange Peters, MD, PhD, discuss data updates from the TROPION-PanTumor01 study that impact the use of antibody-drug conjugates as a therapy option for patients with second-line metastatic non-small cell lung cancer.

Advanced HER2-Positive Breast Cancer: Update on Destiny-Breast03 Data
Mark Pegram, MD, and Sara Tolaney, MD, review data from DESTINY-Breast03 trial and implications of these data for treatment of patients with HER2+ breast cancer going forward.

Screening and Treatment for Lung Cancer: What's Next?
The second part of the webinar Lung Cancer Screening and Treatment: What's Next? focuses on the review of lung cancer screening and treatment status amid the COVID-19 pandemic. Participating faculty include Albert Rizzo, MD, FCCP, FACP, FAASM; James L. Mulshine, MD; Andrea Borondy Kitts, MS, MPH; and Sandip Patel, MD.

New Treatment Options in Chronic GVHD
An expert hematologist/oncologist will highlight the traditional treatment options, unmet needs, and recent advances and approvals in chronic graft vs host disease. Clinical trials will be described as well as novel agents on the horizon.

Updates in CLL: A Closer Look at Adverse Events
Carrie Lenneman, MD, MSCI, and Farrukh Awan, MD, discuss adverse events associated with treating chronic lymphocytic leukemia, particularly when utilizing BTK inhibitors.

Update from HER2CLIMB in Relapsed Refractory HER2-Positive Breast Cancer
Implications for treating patients with progressive, unresectable locally advanced or metastatic HER2-positive breast cancer with tucatinib in combination with capecitabine and trastuzumab.

Post-Conference Perspectives: Chronic Lymphocytic Leukemia
Experts share their perspective on the optimal management of chronic lymphocytic leukemia in light of recent clinical data for novel targeted therapies.

Rare Drivers in Metastatic Non-Small-Cell Lung Cancer with a Focus on EGFR Exon 20 Insertion Mutations
Expert thoracic oncologists discuss the importance of comprehensive molecular testing and optimal use of novel targeted agents in metastatic non-small cell lung cancer.

Post-Conference Perspectives: Myeloproliferative Neoplasms
Key opinion leaders in the treatment of myeloproliferative neoplasms, Pankit Vachhani, MD, and Jamile Shammo, MD, share expert perspectives on ruxolitinib for patients with primary myelofibrosis and polycythemia vera.


PSMA-Targeted Radioligand Therapies in Advanced Prostate Cancer
The rationale behind the use of lutetium-177-PSMA-617, a targeted radioligand therapy, in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer.

The Evolving Role of NGS and Germline Sequencing in Patients with Advanced and Metastatic Cancer
Experts discuss recent data on next generation sequencing and germline testing in patients with advanced and metastatic cancer.

Uveal Melanoma
Drs Richard D. Carvajal and Marlana M. Orloff describe the rationale for treating uveal melanoma with tebentafusp and provide insight on assessing treatment response and managing treatment-related adverse events.

Tipifarnib in HRAS-mutant Head and Neck Squamous Cell Carcinoma
Glenn Hanna, MD, and Nabil F. Saba, MD, FACP, discuss recent data on use of tipifarnib in HRAS-mutant head and neck squamous cell carcinoma.

Tucatinib in Combination with Trastuzumab and Capecitabine in HER2-Positive Metastatic Breast Cancer
Sara A. Hurvitz, MD, discusses updated results of the HER2CLIMB trial of tucatinib in combination with trastuzumab and capecitabine in patients with HER2-positive metastatic breast cancer.

Antibody-Drug Conjugates in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Best practices when prescribing and managing antibody-drug conjugate therapy as treatment for relapsed/refractory diffuse large B-cell lymphoma.

Post-Conference Perspectives: Hormone Receptor-Positive Advanced Breast Cancer
Nicholas McAndrew, MD, MSCE provides his perspective on how findings reported at ASCO 2021 will impact treatment of patients with PIK3CA-mutated HR+, HER2- advanced breast cancer. In this series, Dr. McAndrew reviews the overall survival results from MONALEESA-3, the joint analysis of SOLAR-1 and X2101, the design and outcomes of the BYLieve trial, and real-world clinical outcomes using alpelisib in patients with PIK3CA-mutated HR+, HER2- advanced breast cancer.

After COVID-19: Lung Cancer Screening and Treatment
This expert panel focuses in on the significance of lung cancer screening and treatment approaches following the COVID-19 pandemic.

ZUMA-3: CAR T Therapy for Adult Patients With ALL
Key opinion leaders in hematology oncology, Eunice Wang, MD and Bijal Shah, MD, MS, review the results of the ZUMA trial of CAR T cell therapy in adult patients with relapsed/refractory ALL.

OncLive News Network: On Location at ASCO 2021
Join us LIVE at this year's virtual 2021 ASCO Annual Meeting! OncLive® will broadcast a series of interviews with top thought leaders in breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic malignancies, and hematologic malignancies. The experts will share their insights and reactions to the pivotal data presented during the conference.

Post-Conference Perspectives: RxPONDER, SABCS 2020
Priyanka Sharma, MD, and Lajos Pusztai, MD, PhD, discuss the practice-changing results and real-world implications of the RxPONDER trial for patients with HR+ HER2- breast cancer.

Post Conference Perspectives: Trilaciclib, a New Option for Chemotherapy-Induced Myelosuppression
Ralph Boccia, MD and Jim Schwartz, RPh provide key insights into the recent FDA approval of trilaciclib and discuss its impact on the treatment landscape for extensive-stage small cell lung cancer.

The Next Steps for CAR T-Cell Therapy in DLBCL
Amit Patel, BSc, MBBS, PhD, reviews key takeaways from the 2021 European Society for Blood and Marrow Transplantation symposium regarding the use of CAR T-cell therapy for patients with relapsed/refractory diffuse large B-cell lymphoma.



